GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zeo ScientifiX Inc (OTCPK:ZEOX) » Definitions » Debt-to-EBITDA

Zeo ScientifiX (Zeo ScientifiX) Debt-to-EBITDA : -0.17 (As of Jan. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zeo ScientifiX Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zeo ScientifiX's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $673 Mil. Zeo ScientifiX's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $17 Mil. Zeo ScientifiX's annualized EBITDA for the quarter that ended in Jan. 2024 was $-3,976 Mil. Zeo ScientifiX's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was -0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Zeo ScientifiX's Debt-to-EBITDA or its related term are showing as below:

ZEOX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.69   Med: -0.11   Max: -0.03
Current: -0.69

During the past 13 years, the highest Debt-to-EBITDA Ratio of Zeo ScientifiX was -0.03. The lowest was -0.69. And the median was -0.11.

ZEOX's Debt-to-EBITDA is ranked worse than
100% of 273 companies
in the Biotechnology industry
Industry Median: 1.3 vs ZEOX: -0.69

Zeo ScientifiX Debt-to-EBITDA Historical Data

The historical data trend for Zeo ScientifiX's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zeo ScientifiX Debt-to-EBITDA Chart

Zeo ScientifiX Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.41 -0.04 -0.07 -0.13 -0.11

Zeo ScientifiX Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.09 -0.16 -0.18 -0.17

Competitive Comparison of Zeo ScientifiX's Debt-to-EBITDA

For the Biotechnology subindustry, Zeo ScientifiX's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeo ScientifiX's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Debt-to-EBITDA falls into.



Zeo ScientifiX Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zeo ScientifiX's Debt-to-EBITDA for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.68 + 0.013) / -6.069
=-0.11

Zeo ScientifiX's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(673 + 17) / -3976
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.


Zeo ScientifiX  (OTCPK:ZEOX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Zeo ScientifiX Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zeo ScientifiX's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zeo ScientifiX (Zeo ScientifiX) Business Description

Traded in Other Exchanges
N/A
Address
3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its product candidate, Zofinis an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD and Osteoarthritis. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.
Executives
Skycrest Holdings, Llc 10 percent owner 1930 HARRISON STREET, SUITE 204, HOLLYWOOD FL 33020
Harry L. Leider director, officer: CEO and Director C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Howard Lawrence Golub officer: Executive Vice President & CSO 23648 SEPTEMBER SUN SQ, ASHBURN VA 20148
Matthew Phillip Sinnreich officer: COO and Acting CEO 4045 SHERIDAN AVENUE, SUITE 239, MIAMI BEACH FL 33139
Steven Jerry Glauser director 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Leathem S Stearn director 2306 BAY DRIVE, POMPANO BEACH FL 33062
Charles Luther Bretz director 58 N. CHICAGO ST, 2ND FLOOR, JOLIET IL 60432
Bhupendra Kumar Modi director 6 MARINA BOULEVARD, #63-18, THE SALE @ MARINA BAY U0 018985
Gurvinder Pal Singh director E - 128, FIRST FLOOR, GREATER KAILASH - II, NEW DELHI K7 110048
John F Chiste director
Ryan C Likes officer: Chief Operating Officer 1116 MEADOWBROOK AVE., LOS ANGELES CA 90019
Greyt Ventures, Llc 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Wendy Grey 10 percent owner GREYT VENTURES, LLC, 20533 BISCAYNE BOULEVARD, SUITE 648, AVENTURA FL 33180
Ian T Bothwell 10 percent owner, officer: Chief Financial Officer 77 530 ENFIELD LANE, BLDG D, PALM DESERT CA 92211
Albert Mitrani director, officer: Chief Executive Officer 4045 SHERIDAN AVE., SUITE 239, MIAMI BEACH FL 33140